eli lilly trials retatrutide and Company's triple agonist, retatrutide, successful in two additional phase 3 obesity trials, delivering significant improvements in weight and A1C Eli Lilly's triple hormone drug

While this preliminary research is intriguing, randomized controlled trials are necessary to determine whether glucosamine supplementation can reliably improve outcomes for those with IBD

1,2 As scientists continue to investigate established and new therapeutic applications, GLP-1 receptor (GLP-1R) agonists such as semaglutide, dulaglutide, and tirzepatide have become increasingly relevant tools in preclinical research

In whats known as the SELECT trial, co-authored by UT Southwestern endocrinologist Ildiko Lingvay, M.D., M.P.H., M.S.C.S., 44% of patients using semaglutide lost more than 10% of their body weight within two years, and 11% of patients lost more than 20% more than enough to improve fertility

This combination allows researchers to explore how multiple compounds may work together